TPOXX (Tecovirimat) Operational Planning Guide — Information for Providing Therapeutics for Persons with Mpox
Updated July 2023
The U.S. government is working with state, local, Tribal, and territorial partners to carry out a national strategy to provide vaccines and therapeutics to treat individuals with mpox (formally known as monkeypox).1 This guide is provided to aid state, territorial, Tribal nations, and local health officials in their planning and response efforts.
Anyone, regardless of gender identity or sexual orientation, can get mpox if they have close contact with someone with an active mpox virus infection. Most of those affected in the current global outbreak are gay, bisexual, or other men who have sex with men. Cases have also been reported, to a lesser extent, among women and children and adolescents.2
On August 4, 2022, the Biden Administration declared mpox a federal public health emergency (PHE). The US Department of Health and Human Services (HHS) rapidly expanded access to thousands of patient courses of TPOXX (tecovirimat) for treatment of mpox infections as outlined in Treatment Information for Healthcare Professionals | Mpox | Poxvirus | CDC. The PHE expired on January 31, 2023; however, HHS remains committed to continuing to make TPOXX available to those who qualify for treatment. Oral TPOXX treatment for mpox is available through voluntary participation in the Study of Tecovirimat for Human Mpox Virus (STOMP), sponsored by the National Institutes of Health (NIH).
